Suppr超能文献

睡眠障碍与纤维肌痛。

Sleep disorders and fibromyalgia.

机构信息

Departamento de Psicobiologia, Universidade Federal de São Paulo, Avenida Angélica 1996, Andar 1, São Paulo 01228-200, Brazil.

出版信息

Curr Pain Headache Rep. 2011 Oct;15(5):347-57. doi: 10.1007/s11916-011-0213-3.

Abstract

Disordered sleep is such a prominent symptom in fibromyalgia that the American College of Rheumatology included symptoms such as waking unrefreshed, fatigue, tiredness, and insomnia in the 2010 diagnostic criteria for fibromyalgia. Even though sleep recording is not part of the routine evaluation, polysomnography may disclose primary sleep disorders in patients with fibromyalgia, including obstructive sleep apnea and restless leg syndrome. In addition, genetic background and environmental susceptibility link fibromyalgia and further sleep disorders. Among nonpharmacological treatment proposed for sleep disturbance in fibromyalgia, positive results have been obtained with sleep hygiene and cognitive-behavioral therapy. The effect of exercise is contradictory, but overweight or obese patients with fibromyalgia should be encouraged to lose weight. Regarding the approved antidepressants, amitriptyline proved to be superior to duloxetine and milnacipran for sleep disturbances. New perspectives remain on the narcolepsy drug sodium oxybate, which recently was approved for sleep management in fibromyalgia.

摘要

睡眠紊乱是纤维肌痛的一个突出症状,以至于美国风湿病学会在 2010 年纤维肌痛的诊断标准中纳入了诸如睡醒后仍不清醒、疲劳、乏力和失眠等症状。尽管睡眠记录不是常规评估的一部分,但多导睡眠图可能会揭示纤维肌痛患者的主要睡眠障碍,包括阻塞性睡眠呼吸暂停和不安腿综合征。此外,遗传背景和环境易感性将纤维肌痛与进一步的睡眠障碍联系起来。在针对纤维肌痛睡眠障碍提出的非药物治疗中,睡眠卫生和认知行为疗法已取得积极效果。运动的效果则相互矛盾,但对于纤维肌痛伴超重或肥胖的患者,应鼓励其减轻体重。至于已批准的抗抑郁药,阿米替林在改善睡眠障碍方面优于度洛西汀和米那普仑。对于最近被批准用于纤维肌痛睡眠管理的新型发作性睡病药物羟丁酸钠,仍有新的研究视角。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验